Search PubMed⌕ Search

Biomedical subjects

H Ording

Publications and source records attributed to H Ording.

At least 55 records · Page 3Linked to original sources

In vitro diagnosis of susceptibility to malignant hyperthermia: comparison between dynamic and static halothane and caffeine tests.

In vitro tests for the diagnosis of malignant hyperthermia susceptibility were performed in 105 patients and 20 normal controls according to the protocol of the European MH Group. Results of dynamic halothane and caffeine tests (in which muscle bundle length is cyclically changed) were compared to those of static tests (constant muscle bundle length). Overall, no significant differences between dynamic and static tests were found in threshold concentrations eliciting contractures. Identical diagnostic results with dynamic and static tests were obtained in 94.3% with halothane and in 88.9% with caffeine. The magnitude of contractures was, however, significantly greater in the dynamic than in the static halothane test for halothane concentrations less than 3%, but this did not influence diagnosis. The results indicate that dynamic tests are not superior to static tests, but several tests should be performed to enhance diagnostic safety.

Caffeine↗

In vitro diagnosis of susceptibility to malignant hyperthermia: evaluation of tests with halothane-caffeine, potassium chloride, suxamethonium and caffeine-suxamethonium.

Susceptibility to MH was determined in 77 patients according to the protocol of the European MH Group. Additional muscle bundles were used for diagnostic in vitro tests with caffeine in the presence of 1% halothane, potassium chloride, suxamethonium, and caffeine-suxamethonium. Significant differences between MH-susceptible (MHS) and MH-negative (MHN) patients were obtained with the halothane-caffeine test and the potassium chloride test, whereas no differences were found with the suxamethonium test. In the test with caffeine-suxamethonium, a different response to caffeine but not to suxamethonium was obtained. In all tests there was an overlap in results between MHS and MHN groups, and the predictive values of the tests ranged between 63 and 95%. Prior small doses of caffeine followed by a 4 mmol/l dose of caffeine elicited significantly smaller contractures than 4 mmol/l given as the first dose of caffeine. This underlines the necessity of a common protocol for performance and interpretation of diagnostic tests for MH.

Caffeine↗

A new infusion design for atracurium and vecuronium.

An infusion technique, designed to reduce the duration of period of no response to nerve stimulation following atracurium (Group I) and vecuronium (Group 2), was studied in 30 patients during neurolept anaesthesia. For intubation a combination of a small bolus injection of the relaxant (ED50) and a continuous infusion were administered. The tactile response to nerve stimulation was used to quantify the degree of relaxation and to adjust the speed of infusion. On the other arm the mechanical twitch was recorded blindly for control. Good to excellent intubation conditions were obtained in 4.3 min with atracurium and in 4.0 min with vecuronium. The total dose given for intubation was 0.36 mg kg-1 atracurium (0.24-0.49 mg kg-1) and 0.064 mg kg-1 vecuronium (0.046-0.084 mg kg-1). The period of no response was zero in seven patients in Group I and in four patients in Group 2. In the remaining patients in Group I the period of no response ranged from 5.0-25.0 min, median 10.9 min, and in Group 2 from 2.5-15.6 min, median 9.5 min. At the time of extubation the train-of-four ratio was 0.71 and 0.72 in Group I and 2, respectively. It is concluded that it is possible to achieve a stable, adjustable, and easily reversible block with this technique, even during surgery of short duration.

Adult↗

Atracurium and its antagonism by neostigmine (plus glycopyrrolate) in patients susceptible to malignant hyperthermia.

Forty patients undergoing diagnostic muscle biopsy as part of investigation for malignant hyperthermia (MH) were given atracurium 0.45 +/- 0.10 mg kg-1 for muscle paralysis. The neuromuscular blockade was antagonized with neostigmine 2.4 +/- 0.4 mg given with glycopyrrolate 0.47 +/- 0.09 mg. Rectal, muscle and skin temperatures and blood lactate concentration and venous Pco2 were measured before, during and after anaesthesia. Susceptibility to MH was established by in vitro contracture tests according to the regimen of the European MH Group. Fifteen patients were susceptible to MH (MHS), 19 were MH-negative (MHN) and six were MH-equivocal (MHE). No side effects of the drugs were noted. There were no differences between the three groups of patients in any of the measurements.

Adult↗

Ketanserin and malignant hyperthermia in pigs.

Four Danish landrace pigs susceptible to MH were challenged with halothane and suxamethonium on six occasions after pretreatment with the serotonin-S2 antagonist ketanserin 0.4 mg/kg (three animals) or 4 mg/kg (three animals). The animals developed typical MH on all occasions despite the pretreatment. Dantrolene remains the only specific drug for prevention and treatment of MH.

Animals↗

Precurarization with vecuronium and pancuronium in awake, healthy volunteers: the influence on neuromuscular transmission and pulmonary function.

The influence of pretreatment with pancuronium and vecuronium on the neuromuscular transmission was compared in 24 healthy, awake, non-premedicated volunteers using train-of-four (TOF) nerve stimulation and measurement of respiratory frequency, vital capacity, inspiratory force and peak expiratory flow (PEF). The subjects were randomly allocated to one of three groups. Each subject received one dose of pancuronium and one dose of vecuronium: Group I pancuronium 0.01 mg/kg and vecuronium 0.005 mg/kg; Group II pancuronium 0.01 mg/kg and vecuronium 0.01 mg/kg and Group III pancuronium 0.01 mg/kg and vecuronium 0.015 mg/kg intravenously. The median TOF ratio decreased significantly in Groups I and II following both pancuronium and vecuronium. The TOF ratio following vecuronium in Group II was significantly lower compared to the TOF ratio following vecuronium in Group I. Only PEF decreased significantly in Group I following pancuronium and in Group II following both pancuronium and vecuronium. There was no significant difference between Group I and Group II regarding the number of subjects with signs or symptoms of partial neuromuscular blockade. Following vecuronium 0.005 mg/kg, one subject was unable to swallow and the twitch height decreased to 0.25. In Group II one subject was unable to lift her head and had difficulty in swallowing following pancuronium 0.01 mg/kg. Only four subjects entered Group III because of an unacceptably high frequency of signs and symptoms of partial neuromuscular blockade and a decrease in median TOF ratio to 0.64 following vecuronium. The subjects felt it difficult to swallow, and one subject could just sustain head lift for 10 s following vecuronium 0.015 mg/kg.(ABSTRACT TRUNCATED AT 250 WORDS)

Consciousness↗

Dose-response curves for vecuronium during halothane and neurolept anaesthesia: single bolus versus cumulative method.

The purpose of this study was to compare the incremental, cumulative dose method and the single bolus injection technique for construction of dose-response curves for vecuronium. Dose-response curves were determined in 77 patients divided into four groups according to the anaesthetic given and the method used for construction of dose-response curves. The regression lines corresponding to the four dose-response curves were found to be parallel. For vecuronium ED50 during neurolept anaesthesia was found to be 28 micrograms kg-1 with the single bolus injection technique and 35.2 micrograms kg-1 with the incremental, cumulative dose method (P less than 0.05). During halothane anaesthesia, ED50 was found to be 25.7 micrograms kg-1 and 26.2 micrograms kg-1, respectively (P greater than 0.05). Potentiation of vecuronium by halothane was found with the cumulative method only. It is concluded that the incremental, cumulative dose method is not suitable for potency determinations of vecuronium.

Adult↗

Edrophonium and neostigmine for reversal of the neuromuscular blocking effect of vecuronium.

The effect of edrophonium for reversal of the non-depolarizing neuromuscular blockade produced by a continuous infusion of vecuronium was compared to that of neostigmine in 20 adult patients during neurolept anaesthesia. When antagonism was attempted at 10% twitch height recovery, reversal time to a train-of-four ratio of 0.7 was significantly shorter following neostigmine 0.04 mg/kg than after edrophonium 0.75 mg/kg (9.8 min and 18.7 min, respectively) but the same after edrophonium 1.5 mg/kg (10.3 min). There was no statistically significant difference in reversal time between neostigmine 0.04 mg/kg given at 10% twitch height and edrophonium 0.75 mg/kg given at 25% twitch height recovery (6.0 min). Additional doses of atropine were necessary following edrophonium 1.5 mg/kg.

Adult↗

Malignant hyperthermia triggered by heating in anaesthetized pigs.

Three malignant hyperthermia susceptible (MHS) and three normal Danish landrace pigs were heated using a water-heated mattress, warm blankets and warm intravenous saline during anaesthesia with barbiturate and 50% nitrous oxide in oxygen. The MHS pigs developed typical malignant hyperthermia (MH) at a rectal temperature of 41.0 +/- 0.7 degrees C, whereas the normal pigs tolerated heating to the same temperature without any ill effects. Haemodynamic and metabolic findings during MH were similar to those previously reported for anaesthetic-induced MH in pigs. Heat intolerance may thus be one factor in the genesis of MH.

Anesthesia↗

Incidence of malignant hyperthermia in Denmark.

Questionnaires were sent to all anesthesia departments in Denmark to determine the total number of anesthetics given per year, and the distribution of different types of anesthesia. All cases of suspected malignant hyperthermia forwarded to the Danish Malignant Hyperthermia Register during a 6.5 yr period were reviewed and divided into subgroups according to clinical criteria. The incidence of suspected malignant hyperthermia in these subgroups was calculated in relation to type of anesthesia. The results are based on information about 386,250 anesthetics and 154 cases of suspected malignant hyperthermia. All cases of malignant hyperthermia occurred during general anesthesia, and more than 75% during anesthesia with a combination of potent inhalation agents and succinylcholine. The incidence of fulminant malignant hyperthermia was low: 1 in 250,000 total anesthetic procedures, but 1 in 62,000 anesthetic procedures with a combination of potent inhalation agents and succinylcholine. Masseter spasm occurred in 1 of 12,000 anesthetic procedures in which succinylcholine was administered. Suspicion of malignant hyperthermia was raised in 1 of 16,000 anesthetics total, but in 1 of 4,200 anesthetics with the above-mentioned combination of agents.

Adolescent↗

Investigation of malignant hyperthermia in Denmark and Sweden.

Units for the investigation of susceptibility to malignant hyperthermia (MH) were set up in Denmark in 1977 and in Sweden in 1981. Two hundred and ten patients from 76 families have been investigated. The diagnosis of MH susceptibility (MHS) was made by in vitro exposure of muscle from vastus medialis to halothane and to caffeine. MHS criteria for the patients in this paper were established from examination of 31 control biopsies, obtained from the same muscle and with the same anaesthesia as the MH patients. The criteria have since been changed to those presented elsewhere in this issue. In our laboratories the halothane test (exposure to 0.5-2% halothane) was the more sensitive: 88% of MHS patients reacted to it. The caffeine test was positive in 68% of MHS patients, 0.5-2.0 mmol litre-1 solutions being the most discriminating. Forty-two percent of MHS patients reacted to only one test. Fulminant MH was the most common reason for investigation; all these families contained MHS members. Masseter spasm occurred as sole sign in 21 families, of which 11 were MHS. Only 10% of MHS patients had other signs or symptoms of neuromuscular disease such as muscle cramps or muscular dystrophy. Three families had experienced sudden infant death syndrome (SIDS), and two teenage brothers in a MHS family died suddenly, but death was unrelated to anaesthesia.

Adolescent↗

Dose-response relationships and neuromuscular blocking effects of vecuronium pancuronium during ketamine anaesthesia.

The dose-response curves of vecuronium and pancuronium were compared during ketamine anaesthesia in 60 patients (ASA I). The relationship between the probit transformed depression of twitch height and the logarithm of the dose was analysed by linear regression. Vecuronium was found to be 1.2 times more potent than pancuronium. ED50 of vecuronium and pancuronium were 30.5 microgram kg-1 and 37.0 microgram kg-1, and the ED95 45.6 microgram kg-1 and 59.5 microgram kg-1, respectively. Using equipotent doses of vecuronium and pancuronium (1.6 ED95) indices of neuromuscular blockade were compared in a further 20 patients (ASA I). No statistically significant difference was found in onset time. The duration of action following vecuronium was significantly shorter than after pancuronium. The time to 25% recovery of twitch height following vecuronium 73 microgram kg-1 was 22.2 min compared with 66.6 min following pancuronium 99 microgram kg-1. Following supplementary doses of vecuronium, a statistically significant increase in duration of action was seen following the fourth and fifth doses. Reversal time of vecuronium to a train-of-four ratio of 0.7 was significantly shorter than that of pancuronium (8.3 min and 13.6 min, respectively).

Adult↗

Effect of vecuronium and pancuronium on cardiac performance and transmural myocardial perfusion during ketamine anaesthesia.

The haemodynamic effects of vecuronium and pancuronium were studied in 20 healthy patients during diazepam/ketamine anaesthesia. Anaesthesia was induced with glycopyrrolate 3 micrograms/kg, diazepam 0.3 mg/kg and ketamine 1.0 mg/kg as a bolus and 1.0 mg/kg over 10 min. After induction, anaesthesia was maintained with ketamine infusion 1.0 mg/kg/h. The lungs were ventilated with 50% nitrous oxide in oxygen. Equipotent doses of vecuronium (74 micrograms/kg) or pancuronium (99 micrograms/kg) were administered for intubation. The thoracic impedance, ECG and phonocardiogram were recorded during the induction of anaesthesia. The results suggest that vecuronium has no cardiovascular effects during ketamine anaesthesia, whereas pancuronium due to its chronotropic effect, causes a deterioration in left ventricular performance.

Anesthesia, General↗

Effects of prenalterol on cardiac performance and transmural myocardial perfusion in patients with chronic renal failure.

The acute haemodynamic effects of the beta-adrenoreceptor agonist, prenalterol, were studied in six patients with chronic end-stage renal failure. Prenalterol 0.8 mg, 1.6 mg, and 3.2 mg was administered i.v. as a bolus, and after the last dose the selective adrenergic beta-1-receptor antagonist metoprolol was administered i.v. in doses of 5 and 10 mg. The haemodynamic effects of the drugs were investigated using impedance cardiography and radionuclide angiocardiography. The main haemodynamic effects were a dose-related chronotropic effect, demonstrated by an increase in heart rate (26%; less than 0.05), and an inotropic effect, shown by an increase in stroke volume index (20%; p less than 0.05) and left ventricular ejection time (12%; p less than 0.05); the cardiac index was increased by 47% (p less than 0.05). Transmural myocardial perfusion (DPTI/SPTI ratio) was decreased by 22% (p less than 0.05) after prenalterol. It is concluded that prenalterol has positive inotropic and chronotropic effects in patients with chronic renal failure, that the improvement in left ventricular performance is at the expense of a decreased transmural myocardial perfusion, and that metoprolol is a specific antidote.

Aged↗

Neuromuscular blocking effects of vecuronium and pancuronium during halothane anaesthesia.

The neuromuscular blocking properties of vecuronium (Org NC 45) and pancuronium were compared in 40 patients during halothane anaesthesia. Onset time was found to be dose-dependent, but no significant difference was found between the two drugs. The duration of action of vecuronium was significantly shorter than pancuronium. Times to 90% recovery of twitch height following vecuronium 0.03 mg kg-1 and 0.057 mg kg-1 were 32.0 min and 44.9 min, respectively, compared with 72.9 min and 124.7 min following equipotent doses of pancuronium (0.042 mg kg-1 and 0.08 mg kg-1). Recovery indices following both doses of vecuronium (10.0 min and 11.8 min) were significantly shorter than after pancuronium (31.0 min and 46.9 min). The reversal times of vecuronium (times from 10% to 90% twitch height recovery) were significantly shorter than those of pancuronium (7.9 min and 7.3 min, respectively, compared with 17.1 min and 17.7 min).

Adult↗

Cardiac effects of vecuronium and pancuronium during halothane anaesthesia.

The cardiac effects of equipotent doses of pancuronium and vecuronium (Org NC 45) were compared in 20 patients, anaesthetized with halothane. Heart rate and arterial pressure were recorded and the systolic time intervals were evaluated from simultaneous tracings of ECG, phonocardiogram and carotid pulse curve. Pancuronium 0.08 mg kg-1 caused a significant increase in heart rate (20%), insignificant changes in arterial pressure and significant changes in systolic time intervals compatible with a minor positive inotropic action. The equipotent dose of vecuronium (0.057 mg kg-1) caused no significant changes in heart rate, arterial pressure or systolic time intervals.

Adult↗